Propanc Biopharma, Inc. (PPCB)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.49 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2026, ended 30 Jun 2026, as filed

Net income

$18.86M

Free cash flow

$5.69M

Return on equity

-200.6%

Return on capital

-151.9%

Debt to equity

0.01

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
5 Jul 2013	Nathanielsz James Andrew Chief Executive Officer	Sold, plan not stated	$4.98K	0.6%
23 Jan 2013	Nathanielsz James Andrew Chief Executive Officer	Sold, plan not stated	$3.00K	0.2%
13 Dec 2012	Nathanielsz James Andrew Chief Executive Officer	Sold, plan not stated	$1.10K	0.1%
14 Sep 2012	Nathanielsz James Andrew Chief Executive Officer	Sold, plan not stated	$1.00K	0.1%
4 Sep 2012	Nathanielsz James Andrew Chief Executive Officer	Sold, plan not stated	$50.00K	2.5%
23 Aug 2012	Nathanielsz James Andrew Chief Executive Officer	Sold, plan not stated	$50.00K	2.5%

29out of 100

Profitability 0

Financial strength 47

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan